Revisiting bleomycin from pathophysiology to safe clinical use (Journal article)

Froudarakis, M./ Hatzimichael, E./ Kyriazopoulou, L./ Lagos, K./ Pappas, P./ Tzakos, A. G./ Karavasilis, V./ Daliani, D./ Papandreou, C./ Briasoulis, E.


Bleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced lung injury (BILI), which is associated with significant morbidity and a mortality rate of 1-3%. Diagnosis of BILI is one of exclusion and physicians involved in the care of HL and GCT patients should be alerted. Pharmacogenomic studies could contribute towards the identification of molecular predictors of bleomycin toxicity on the aim to optimize individual use of bleomycin. We review all existing data on bleomycin's most recent integrated chemical biology, molecular pharmacology and mature clinical data and provide guidelines for its safe clinical use.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/9077
ISSN: 1879-0461
Link: http://www.ncbi.nlm.nih.gov/pubmed/23312772
http://ac.els-cdn.com/S1040842812002491/1-s2.0-S1040842812002491-main.pdf?_tid=9bbc0a3a-4075-11e3-9cf1-00000aacb362&acdnat=1383036142_0d0e1a8461bda219572d1d088dd18a0f
Publisher: Elsevier
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Froudarakis-2013-Revisiting bleomycin.pdf1.27 MBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/9077
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.